Publications

BibTex format

@article{Chari:2018:10.1182/bloodadvances.2017015545,
author = {Chari, A and Stewart, AK and Russell, SD and Moreau, P and Herrmann, J and Banchs, J and Hajek, R and Groarke, J and Lyon, AR and Batty, GN and Ro, S and Huang, M and Iskander, KS and Lenihan, D},
doi = {10.1182/bloodadvances.2017015545},
journal = {Blood Advances},
pages = {1633--1644},
title = {Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials},
url = {http://dx.doi.org/10.1182/bloodadvances.2017015545},
volume = {2},
year = {2018}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Carfilzomib is a selective proteasome inhibitor approved for the treatment of relapsed and/or refractory multiple myeloma (RRMM). It has significantly improved outcomes, including overall survival (OS), and shown superiority vs standard treatment with lenalidomide plus dexamethasone and bortezomib plus dexamethasone. The incidence rate of cardiovascular (CV) events with carfilzomib treatment has varied across trials. This analysis evaluated phase 1-3 trials with >2000 RRMM patients exposed to carfilzomib to describe the incidence of CV adverse events (AEs). In addition, the individual CV safety data of >1000 patients enrolled in the carfilzomib arm of phase 3 studies were compared with the control arms to assess the benefit-risk profile of carfilzomib. Pooling data across carfilzomib trials, the CV AEs (grade ≥3) noted included hypertension (5.9%), dyspnea (4.5%), and cardiac failure (4.4%). Although patients receiving carfilzomib had a numeric increase in the rates of any-grade and grade ≥3 cardiac failure, dyspnea, and hypertension, the frequency of discontinuation or death due to these cardiac events was low and comparable between the carfilzomib and control arms. Serial echocardiography in a blinded cardiac substudy showed no objective evidence of cardiac dysfunction in the carfilzomib and control arms. Moreover, carfilzomib had no significant effect on cardiac repolarization. Our results, including the OS benefit, showed that the benefit of carfilzomib treatment in terms of reducing progression or death outweighed the risk for developing cardiac failure or hypertension in most patients. Appropriate carfilzomib administration and risk factor management are recommended for elderly patients and patients with underlying risk factors.
AU  - Chari,A
AU  - Stewart,AK
AU  - Russell,SD
AU  - Moreau,P
AU  - Herrmann,J
AU  - Banchs,J
AU  - Hajek,R
AU  - Groarke,J
AU  - Lyon,AR
AU  - Batty,GN
AU  - Ro,S
AU  - Huang,M
AU  - Iskander,KS
AU  - Lenihan,D
DO  - 10.1182/bloodadvances.2017015545
EP  - 1644
PY  - 2018///
SN  - 2473-9529
SP  - 1633
TI  - Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials
T2  - Blood Advances
UR  - http://dx.doi.org/10.1182/bloodadvances.2017015545
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000438355400016&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - http://hdl.handle.net/10044/1/63042
VL  - 2
ER  -

Download

DrAlexanderLyon

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)